Mavacamten is the first and only FDA-approved cardiac myosin inhibitor to treat obstructive hypertrophic cardiomyopathy (HCM). An important factor to the success of the VALOR HCM trial was the participation of specialized cardiac sonographers and imagers.
Milind Desai, MD, MBA speaks with Jeanne Drinko, Amy Kanta and Anne Campbell about the importance of cardiac imaging.


Learn more about C5 Research at Cleveland Clinic.
https://my.clevelandclinic.org/research/c5research

Looking to refer a patient? Please reach out to our Physician Referral team Mon. - Fri., 8 a.m. - 5 p.m. (ET), toll-free 800.223.2273, ext. 49162

Clinicians should consider statin therapy for primary prevention. Vikas Sunder, MD, a cardiologist in Preventive Cardiology, reviews indicators and considerations for statin initiation as well as barriers to adherence.

Learn more about the Section of Preventive Cardiology and Rehabilitation
https://my.clevelandclinic.org/departments/heart/depts/preventive-cardiology-rehabilitation

Looking to refer a patient? Please reach out to our Physician Referral team Mon. - Fri., 8 a.m. - 5 p.m. (ET), toll-free 800.223.2273, ext. 49162

Roy Chung, MD sits down with Thomas Callahan, MD to talk about the challenges of left bundle branch area pacing, particularly management after implant. Dr. Chung has much experience with conduction system pacing and shares his experience during this podcast.

Learn more about Cleveland Clinic's Pacemaker and Defibrillator Lead Extraction Center
https://my.clevelandclinic.org/departments/heart/depts/pacemaker-defibrillator

Interested in learning more about lead management? Join experts in the field at LEADconnection.
https://leadconnection.org/

Amanda Vest, MBBS, discusses metabolic challenges in heart failure, new opportunities with obesity and cachexia. Learn more about Cleveland Clinic's Center for Heart Failure Treatment and Recovery.

Patients with hypertrophic obstructive cardiomyopathy can suffer from arrhythmias before and after septal myectomy. Dr. Nicholas Smedira specializes in the surgical management of LVOT obstruction and discusses the impact of left ventricular outflow obstruction on the heart's conduction system.

Learn more about the Hypertrophic Cardiomyopathy Center
https://my.clevelandclinic.org/departments/heart/depts/hypertrophic-cardiomyopathy

In this episode, Amar Krishnaswamy, MD, leads a discussion on the role of percutaneous mitral valve therapies in 2024. Learn more about Cleveland Clinic's Mitral and Tricuspid Valve Center: https://my.clevelandclinic.org/departments/heart/depts/mitral-and-tricuspid-valve-center

Left ventricular outflow tract (LVOT) obstruction is a condition that restricts blood flow from the left ventricle of the heart. LVOT obstruction is defined as a peak gradient of at least 30 mm Hg at rest or with provocation. A peak gradient of at least 50 mm Hg is usually the threshold for surgical or percutaneous intervention. Dr. Nicholas Smedira specializes in the surgical management of LVOT obstruction and discusses considerations for assessment and intervention.

In this episode, Dr. Edward Soltesz provides an overview with a case presentation, and J. Emanuel Finet, MD, discusses treatment options for end stage heart failure and considerations for heart transplantation. Learn more about Tall Rounds online. http://2207941.mediaspace.kaltura.com/category/Tall+Rounds/75663251